- Home
- BUR vs RARE Comparison
BUR vs RARE Comparison
Compare BUR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUR
- RARE
- Stock Information
- Founded
- BUR 2009
- RARE 2010
- Country
- BUR Guernsey
- RARE United States
- Employees
- BUR N/A
- RARE N/A
- Industry
- BUR Finance: Consumer Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BUR Finance
- RARE Health Care
- Exchange
- BUR Nasdaq
- RARE Nasdaq
- Market Cap
- BUR 2.8B
- RARE 2.6B
- IPO Year
- BUR 2010
- RARE 2014
- Fundamental
- Price
- BUR $12.99
- RARE $30.64
- Analyst Decision
- BUR Strong Buy
- RARE Strong Buy
- Analyst Count
- BUR 2
- RARE 14
- Target Price
- BUR $18.00
- RARE $86.64
- AVG Volume (30 Days)
- BUR 1.6M
- RARE 1.3M
- Earning Date
- BUR 11-06-2025
- RARE 11-04-2025
- Dividend Yield
- BUR 1.00%
- RARE N/A
- EPS Growth
- BUR N/A
- RARE N/A
- EPS
- BUR 1.08
- RARE N/A
- Revenue
- BUR $443,251,000.00
- RARE $610,159,000.00
- Revenue This Year
- BUR $17.08
- RARE $19.72
- Revenue Next Year
- BUR $9.43
- RARE $23.29
- P/E Ratio
- BUR $11.55
- RARE N/A
- Revenue Growth
- BUR N/A
- RARE 26.77
- 52 Week Low
- BUR $10.70
- RARE $25.81
- 52 Week High
- BUR $15.73
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BUR 44.11
- RARE 52.06
- Support Level
- BUR $12.43
- RARE $30.45
- Resistance Level
- BUR $13.04
- RARE $31.80
- Average True Range (ATR)
- BUR 0.36
- RARE 0.92
- MACD
- BUR -0.10
- RARE 0.09
- Stochastic Oscillator
- BUR 30.68
- RARE 46.89
About BUR Burford Capital Limited
Burford Capital Ltd is a finance firm providing litigation finance, insurance, and risk transfer, law firm lending, corporate intelligence and judgment enforcement, and a wide range of investment activities. It operates in two segments: Principal Finance, which allocates capital to legal finance assets from its balance sheet, primarily as capital provision assets and in limited scope through interests in private funds managed by the company; Asset management and other services, which includes the provision of services to the legal industry, including litigation insurance; and other corporate. The geographical segments include the United States, United Kingdom, Singapore, Hong Kong, China, and, Australia.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.